For instance, the Immunoscore, a standardized immune assay based on the immunohistochemical staining of tumor-infiltrating CD3+ and CD8+ T cells in combination with automated artificial intelligence-assisted signal detection and interpretation, has found its way into international consensus guidelines for the clinical management of CRC disease and has been proven to refine prognosis and significantly improve CRC risk assessment [6,7]. This evidence concerns the gene CD8A and colorectal carcinoma.